Suppr超能文献

新型冠状病毒肺炎患者 ST 段抬高型心肌梗死的流行病学和管理:美国心脏协会新型冠状病毒肺炎心血管疾病注册研究报告。

Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry.

机构信息

Levine Cardiac Intensive Care Unit Thrombolysis in Myocardial Infarction (TIMI) Study Group Cardiovascular Division Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.

Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.

出版信息

J Am Heart Assoc. 2022 May 3;11(9):e024451. doi: 10.1161/JAHA.121.024451. Epub 2022 Apr 26.

Abstract

Background Early reports from the COVID-19 pandemic identified coronary thrombosis leading to ST-segment-elevation myocardial infarction (STEMI) as a complication of COVID-19 infection. However, the epidemiology of STEMI in patients with COVID-19 is not well characterized. We sought to determine the incidence, diagnostic and therapeutic approaches, and outcomes in STEMI patients hospitalized for COVID-19. Methods and Results Patients with data on presentation ECG and in-hospital myocardial infarction were identified from January 14, 2020 to November 30, 2020, from 105 sites participating in the American Heart Association COVID-19 Cardiovascular Disease Registry. Patient characteristics, resource use, and clinical outcomes were summarized and compared based on the presence or absence of STEMI. Among 15 621 COVID-19 hospitalizations, 54 (0.35%) patients experienced in-hospital STEMI. Among patients with STEMI, the majority (n=40, 74%) underwent transthoracic echocardiography, but only half (n=27, 50%) underwent coronary angiography. Half of all patients with COVID-19 and STEMI (n=27, 50%) did not undergo any form of primary reperfusion therapy. Rates of all-cause shock (47% versus 14%), cardiac arrest (22% versus 4.8%), new heart failure (17% versus 1.4%), and need for new renal replacement therapy (11% versus 4.3%) were multifold higher in patients with STEMI compared with those without STEMI (<0.050 for all). Rates of in-hospital death were 41% in patients with STEMI, compared with 16% in those without STEMI (<0.001). Conclusions STEMI in hospitalized patients with COVID-19 is rare but associated with poor in-hospital outcomes. Rates of coronary angiography and primary reperfusion were low in this population of patients with STEMI and COVID-19. Adaptations of systems of care to ensure timely contemporary treatment for this population are needed.

摘要

背景

COVID-19 大流行早期的报告表明,COVID-19 感染可导致冠状动脉血栓形成并引发 ST 段抬高型心肌梗死(STEMI)。然而,COVID-19 患者中 STEMI 的流行病学特征尚不清楚。我们旨在确定因 COVID-19 住院的 STEMI 患者的发病率、诊断和治疗方法以及结局。

方法和结果

从 2020 年 1 月 14 日至 2020 年 11 月 30 日,从参与美国心脏协会 COVID-19 心血管疾病登记处的 105 个站点中,确定了有入院时心电图和院内心肌梗死数据的患者。根据是否存在 STEMI,总结并比较了患者特征、资源利用和临床结局。在 15621 例 COVID-19 住院患者中,有 54 例(0.35%)患者发生院内 STEMI。在 STEMI 患者中,大多数(n=40,74%)接受了经胸超声心动图检查,但只有一半(n=27,50%)接受了冠状动脉造影。所有 COVID-19 和 STEMI 患者中有一半(n=27,50%)未接受任何形式的直接再灌注治疗。与无 STEMI 患者相比,STEMI 患者的总休克发生率(47%比 14%)、心脏骤停发生率(22%比 4.8%)、新发心力衰竭发生率(17%比 1.4%)和需要新肾脏替代治疗的发生率(11%比 4.3%)均高出数倍(<0.050 均)。STEMI 患者的院内死亡率为 41%,而无 STEMI 患者的死亡率为 16%(<0.001)。

结论

COVID-19 住院患者中 STEMI 很少见,但与不良的院内结局相关。该 STEMI 合并 COVID-19 患者人群中,冠状动脉造影和直接再灌注的比例较低。需要对医疗系统进行调整,以确保及时对该人群进行现代治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c16/9238583/6edd850cd4df/JAH3-11-e024451-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验